It has been about a month since the last earnings report for DexCom (DXCM). Shares have lost about 11.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

DexCom is a leading manufacturer of continuous glucose monitors (CGM) that are used by diabetes patients to better monitor, and thus control, their blood sugar levels. A person in a lab coat writing ...

DexCom (NASDAQ:DXCM) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, ...

8 analysts have shared their evaluations of DexCom (NASDAQ:DXCM) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose ...

Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up might have investors contemplating their next ...

DexCom Q4 revenue beat at $1.114B, up 8% Y/Y, but EPS missed at $0.45 vs. $0.50 consensus. FY25 guidance reaffirmed with $4.6B revenue target and 21% operating margin. Get stock picks, daily rankings, ...

After second-quarter sales and earnings outpaced industry watchers' expectations, and newly launched products drove optimistic demand-growth projections, shares in DexCom Inc. (NASDAQ: DXCM) ...